Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2005 1
2006 1
2010 2
2011 2
2012 2
2013 6
2014 5
2015 7
2016 9
2017 7
2018 7
2019 7
2020 3
2021 7
2022 4
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Results by year

Filters applied: . Clear all
Page 1
[Stiff-Person Syndrome].
Matsui N, Tanaka K, Izumi Y. Matsui N, et al. Brain Nerve. 2023 Jun;75(6):749-754. doi: 10.11477/mf.1416202410. Brain Nerve. 2023. PMID: 37287358 Japanese.
[Stiff-Person Syndrome].
Matsui N, Tanaka K, Izumi Y. Matsui N, et al. Brain Nerve. 2021 May;73(5):640-646. doi: 10.11477/mf.1416201808. Brain Nerve. 2021. PMID: 34006698 Japanese.
Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial.
Ohba A, Morizane C, Ueno M, Kobayashi S, Kawamoto Y, Komatsu Y, Ikeda M, Sasaki M, Okano N, Furuse J, Hiraoka N, Yoshida H, Kuchiba A, Sadachi R, Nakamura K, Matsui N, Nakamura Y, Okamoto W, Yoshino T, Okusaka T. Ohba A, et al. Among authors: matsui n. Future Oncol. 2022 Jun;18(19):2351-2360. doi: 10.2217/fon-2022-0214. Epub 2022 May 5. Future Oncol. 2022. PMID: 35510484 Free article.
Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial.
Misawa S, Kuwabara S, Sato Y, Yamaguchi N, Nagashima K, Katayama K, Sekiguchi Y, Iwai Y, Amino H, Suichi T, Yokota T, Nishida Y, Kanouchi T, Kohara N, Kawamoto M, Ishii J, Kuwahara M, Suzuki H, Hirata K, Kokubun N, Masuda R, Kaneko J, Yabe I, Sasaki H, Kaida KI, Takazaki H, Suzuki N, Suzuki S, Nodera H, Matsui N, Tsuji S, Koike H, Yamasaki R, Kusunoki S; Japanese Eculizumab Trial for GBS (JET-GBS) Study Group. Misawa S, et al. Among authors: matsui n. Lancet Neurol. 2018 Jun;17(6):519-529. doi: 10.1016/S1474-4422(18)30114-5. Epub 2018 Apr 21. Lancet Neurol. 2018. PMID: 29685815 Clinical Trial.
Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT.
Amato AA, Hanna MG, Machado PM, Badrising UA, Chinoy H, Benveniste O, Karanam AK, Wu M, Tankó LB, Schubert-Tennigkeit AA, Papanicolaou DA, Lloyd TE, Needham M, Liang C, Reardon KA, de Visser M, Ascherman DP, Barohn RJ, Dimachkie MM, Miller JAL, Kissel JT, Oskarsson B, Joyce NC, Van den Bergh P, Baets J, De Bleecker JL, Karam C, David WS, Mirabella M, Nations SP, Jung HH, Pegoraro E, Maggi L, Rodolico C, Filosto M, Shaibani AI, Sivakumar K, Goyal NA, Mori-Yoshimura M, Yamashita S, Suzuki N, Aoki M, Katsuno M, Morihata H, Murata K, Nodera H, Nishino I, Romano CD, Williams VSL, Vissing J, Zhang Auberson L; RESILIENT Study Extension Group. Amato AA, et al. Neurology. 2021 Mar 23;96(12):e1595-e1607. doi: 10.1212/WNL.0000000000011626. Epub 2021 Feb 17. Neurology. 2021. PMID: 33597289 Free PMC article. Clinical Trial.
Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study.
Koyama T, Shimizu T, Kojima Y, Sudo K, Okuma HS, Shimoi T, Ichikawa H, Kohsaka S, Sadachi R, Hirakawa A, Yoshida A, Ando RM, Ueno T, Yanagaki M, Matsui N, Nakamura K, Yamamoto N, Yonemori K. Koyama T, et al. Among authors: matsui n. Cancer Discov. 2023 Aug 4;13(8):1814-1825. doi: 10.1158/2159-8290.CD-23-0419. Cancer Discov. 2023. PMID: 37369013 Clinical Trial.
Prevalence, Clinical Profiles, and Prognosis of Stiff-Person Syndrome in a Japanese Nationwide Survey.
Matsui N, Tanaka K, Ishida M, Yamamoto Y, Matsubara Y, Saika R, Iizuka T, Nakamura K, Kuriyama N, Matsui M, Arisawa K, Nakamura Y, Kaji R, Kuwabara S, Izumi Y; Japanese SPS Study. Matsui N, et al. Neurol Neuroimmunol Neuroinflamm. 2023 Sep 22;10(6):e200165. doi: 10.1212/NXI.0000000000200165. Print 2023 Nov. Neurol Neuroimmunol Neuroinflamm. 2023. PMID: 37739810 Free PMC article.
Pulmonary cancers across different histotypes share hybrid tuft cell/ionocyte-like molecular features and potentially druggable vulnerabilities.
Yamada Y, Belharazem-Vitacolonnna D, Bohnenberger H, Weiß C, Matsui N, Kriegsmann M, Kriegsmann K, Sinn P, Simon-Keller K, Hamilton G, Graeter T, Preissler G, Ott G, Schölch S, Nakajima N, Yoshizawa A, Haga H, Date H, Thomas RK, Petrini I, Giaccone G, Ströbel P, Marx A. Yamada Y, et al. Among authors: matsui n. Cell Death Dis. 2022 Nov 19;13(11):979. doi: 10.1038/s41419-022-05428-x. Cell Death Dis. 2022. PMID: 36402755 Free PMC article.
72 results